APA (7th ed.) Citation

Lorenz, H., Merkt, W., Brandt, J., Giese, T., Exner, T., Blank, N., . . . Raab, M. (2025). One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel disease. Annals of the rheumatic diseases, 84(7), . https://doi.org/10.1016/j.ard.2025.05.007

Chicago Style (17th ed.) Citation

Lorenz, Hanns-Martin, Wolfgang Merkt, Juliane Brandt, Thomas Giese, Tarik Exner, Norbert Blank, Maria Margarida Souto-Carneiro, Annika Gauss, and Marc-Steffen Raab. "One-year Remission of Therapy-resistant SLE After a Single Course with the Bispecific CD3: BCMA Antibody Teclistamab, but Induction of a Non-infectious Crohn’s-like Inflammatory Bowel Disease." Annals of the Rheumatic Diseases 84, no. 7 (2025). https://doi.org/10.1016/j.ard.2025.05.007.

MLA (9th ed.) Citation

Lorenz, Hanns-Martin, et al. "One-year Remission of Therapy-resistant SLE After a Single Course with the Bispecific CD3: BCMA Antibody Teclistamab, but Induction of a Non-infectious Crohn’s-like Inflammatory Bowel Disease." Annals of the Rheumatic Diseases, vol. 84, no. 7, 2025, https://doi.org/10.1016/j.ard.2025.05.007.